Indications |
Oral Hyperlipidaemias Adult: As sodium: 10-40 mg daily at night, adjusted according to response at 4-wk intervals. Max dose: 40 mg daily. Child: (With familial hypercholestrolaemia) 8-13 yr: 10-20 mg, 14-18 yr: 10-40 mg, dose to be taken once daily. Renal impairment: Moderate to severe: initial dose should not exceed 10 mg daily. Hepatic impairment: Significant impairment: initial dose should not exceed 10 mg daily. |
Contraindications |
Hypersensitivity; active liver disease; childn <8 yr. Pregnancy, lactation. |
Warnings / Precautions |
Severe intercurrent illness increases risk of myopathy, rhabdomyolysis and renal failure; stop pravastatin during illness. Severe renal impairment, monitor regularly renal function and creatine kinase. Women of childbearing potential, use adequate contraception. Preexisting abnormal liver function, monitor serum transaminase. Children. May increase creatine phosphokinase and transaminases levels. |
Adverse Reactions |
GI symptoms, headache, insomnia, chest pain, rash, fatigue, dizziness, myalgia, hypersensitivity, anaphylaxis, angioedema, rhabdomyolysis, renal failure, hepatitis, alopoecia, paraesthesia, impotence, gynaecomastia. |
Drug Interactions |
Fenofibrate, clofibrate, nicotinic acid and gemfibrozil increase risk of myopathy or rhabdomyolysis, use lowest effective dose. Ciclosporin, clarithromycin, itraconazole, ketoconazole and erythromycin increase pravastatin concentrations. Increased risk of bleeding when used with coumarins and fluindione. Decreased serum concentrations when used with efavirenz and rifampicin. See Below for More pravastatin Drug Interactions |
Mechanism of Actions |
Pravastatin inhibits HMG-CoA reductase, the enzyme which catalyses the rate-limiting step in cholesterol biosynthesis. It reduces conc of total cholesterol and LDL (LDL) cholesterol and triglyceride. It produces an increase in high-density lipoprotein (HDL) cholesterol and it increases hepatic cholesterol uptake from blood. Absorption: Rapidly but incompletely absorbed from the GIT (oral). Absolute bioavailability is about 17%. Distribution: Protein-binding: 50% Metabolism: Extensively hepatic. Excretion: Faeces (70%); urine (20%); 1.5-2 hr (elimination half-life). |
Administration |
May be taken with or without food. |
Storage Conditions |
Oral: Store at 25°C. |
ATC Classification |
C10AA03 - pravastatin ; Belongs to the class of HMG CoA reductase inhibitors. Used in the treatment of hyperlipidemia. |
Storage |
Oral: Store at 25°C. |
Available As |
|
Parvastatin Sodium
Post Review about Parvastatin Sodium Click here to cancel reply.
Parvastatin Sodium Containing Brands
Parvastatin Sodium is used in following diseases
Drug - Drug Interactions of Parvastatin Sodium
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.